Omeros Corp (OMER) has released an update to notify the public and investors about its financial commitment initiation.
Omeros Corporation has expanded its royalty agreement with DRI Healthcare Acquisitions, selling an increased share of the royalties from its ophthalmologic product, OMIDRIA, for $115 million. This amendment removes previous annual caps, now allowing DRI to collect all U.S. OMIDRIA royalties until the end of 2031, with potential milestone payments to Omeros if sales targets are met. Omeros retains all OMIDRIA royalties outside the U.S. and any global royalties after 2031, emphasizing the deal’s strategic move for long-term financial planning in the biopharmaceutical industry.
For further insights into OMER financials, check out TipRanks’ Financials page.
For a comprehensive understanding of the announcement, you can read the full document here.
